Interview With OIVD: Reflections On New Office, Evolving Tests And Policies
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of In Vitro Diagnostic Device Evaluation & Safety will continue to streamline its 510(k) process, develop metrics and scorecards and refine compliance strategies in 2004
You may also be interested in...
MDUFMA Update: FDA Tackles Performance Goals, Premarket Review Funding
Year-one implementation of the Medical Device User Fee & Modernization Act was marked by both progress and challenges as FDA worked to build a foundation for meeting new performance goals and to execute some of the 2002 law's more controversial provisions
AmpliChip Microarray Could Take De Novo Premarket Route, FDA Tells Roche
Roche must submit a 510(k) application before commercializing its AmpliChip CYP450 microarray, FDA says in a letter clarifying its regulatory stance on the technology
OIVD Jets Forth With TURBO 510(k) Template, De Novo Reviews
Premarket review times for IVD devices will be cut in half once the FDA Office of In Vitro Diagnostic Device Evaluation & Safety implements its "TURBO 510(k)" electronic template, Deputy Director for New Device Evaluation Donald St. Pierre predicts